Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure
Author:
Affiliation:
1. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Funder
no funding
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2265566
Reference99 articles.
1. Cancer treatment and survivorship statistics, 2022
2. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
3. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
4. The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
5. Screening for anaplastic lymphoma kinase ( ALK ) gene rearrangements in non‐small‐cell lung cancer in New Zealand
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ARE ALECTINIB-INDUCED MYALGIA AND ELEVATION CREATINE PHOSPHOKINASE PREDICTORS OF HIGH RECURRECCE-FREE SURVIVAL?;Art of Medicine;2024-06-29
2. Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report;Heliyon;2024-06
3. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27
4. Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory;Translational Lung Cancer Research;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3